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Abstract
Background: Cases of squamous cell carcinoma (SCC) of the oropharynx were compared with other head and
neck cancer (HNC) anatomic subsites in patients treated at the provincial referral centre for HNC, the Nova Scotia
Cancer Centre (NSCC).
Methods: A retrospective chart review was performed on HNC patients assessed at the NSCC between 2010 and
2011. Patient demographics, disease characteristics, treatment details and outcomes, including recurrence rates and
survival were collected. Data was collected on new and recurrent cases of HNC. This data was compared between
the two types of HNC using chi-square tests for dichotomous categorical variables or Fishers exact test where
appropriate. Wald test was used to compare categorical variables with 3 categories. Continuous variables were
compared using the non-parametric Wilcoxon test.
Results: 318 charts were included in the analysis. 122 (38 %) were oropharyngeal squamous cell carcinomas
(OPSCCs). In terms of disease characteristics, OPSCCs were more likely to be poorly differentiated/undifferentiated
(n = 267, 49(40 %) vs 42(21 %), p < 0.001), non-keratinizing (n = 169, 25(20 %) vs 17(9 %), p < 0.001), greater than
2 cm (n = 253, 72(59 %) vs 78(40 %), p = 0.0061), stage 4 (n = 313, 55(45 %) vs 64(33 %), p = 0.0315) and have had
locoregional nodal spread (n = 315, 103(84 %) vs 55(28 %), p < 0.001). In the subset of 57 patients that had p16
testing, OPSCCs were more likely to be p16(+) (37(30 %) vs 1(1 %), p < .001). There were no significant differences in
terms of Charlson probability of 10 year survival, smoking or alcohol consumption although OPSCC patients were
significantly less likely to have COPD as a co-morbidity (n = 318, 19(16 %) vs 53(27 %), p = 0.0175). Finally, OPSCCs
had less chance for relapse than non-OPSCCs in both univariate (2.119 times less, p=0.0034) and multivariate (1.899
times less, p=0.0505) analyses along with a 1.822 times less overall mortality in a multivariae analysis (p=0.0408).
Conclusions: This analysis suggests that Nova Scotian OPSCCs should be considered distinct from other HNC
lesions, most notably in terms of disease characteristics and prognosis. Specifically, despite a higher association with
disease factors traditionally considered to be linked to poor prognosis, outcomes were actually superior in terms of
relapse and overall mortality.
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Background
Worldwide there are over 550,000 new cases of head
and neck cancer (HNC) reported annually, including an
estimated 130,300 oropharyngeal cancers (OPC) [1, 2].
In Canada, the estimated incience of oral and laryngeal
cancers alone was 5350 in 2014 [3]. Understanding
HNC’s characteristics, its causative factors and poten-
tial differences among HNC subsites is integral to pro-
viding optimal care of HNC patients. Ultimately this
would aid in achieving the goals of disease prevention
and reduction of associated morbidity and mortality in
this population.
It is increasingly apparent that we must consider oro-
pharyngeal squamous cell carcinomas (OPSCCs) separ-
ately from other subsites of head and neck squamous
cell carcinoma (HNSCC) due to a different biologic and
epidemiologic profile. Specifically, the incidence of other
subtypes of HNSCC, including the larynx, oral cavity
and hypopharynx, is declining whereas the incidence of
OPSCCs, particularly in the tonsillar and base of
tongue region, have demonstrated a recent increase in
incidence in the United States (US), Canada, Australia,
Denmark, Japan, Slovakia, the United Kingdom (UK)
and Sweden [4–11].
Additionally, the risk factors to develop OPSCC are
different from those associated with other HNSCC sites.
The principal risk factors for HNC are cigarette smoking
and alcohol consumption [12]. In North America there
has been a demonstrable decline in both of these
cancer-associated activities, most notably in smoking
[13, 14]. In Canada, from 1992–2007, these trends have
been mirrored by the decline in incidence of oral cavity
tumours and other HNSCC tumours including hypo-
pharynx, larynx and nasopharynx tumours [4]. These
trends have not been seen in OPSCCs, however, which
have shown an increase in incidence in men and women
within the same time period [4]. Similar epidemiologic
trends have been appreciated in populations around the
world [4–11].
Further, the human papilloma virus (HPV) has been
recognized as a contributing factor in the development
of OPSCCs more frequently than in other HNSCCs,
likely accounting for some of the disparity in incidence
trends between these two groups [6, 8, 9, 15, 16]. HPV
has been established as central to the development of
cervical squamous neoplasias, with the virus being
detected in as high as 99.7 % of cases [17]. Research
has recently shown that in the US, HPV positive (+) tu-
mours have also become the most prominent form of
OPSCC, suggesting that HPV exposure has surpassed
smoking and alcohol as the most significant risk factor
for this subsite [11].
OPSCC is more commonly diagnosed in younger males
with a history of high-risk sexual behavior and marijuana
use [10, 18]. This stands in contrast to the “classic”
HNSCC risk factors of heavy tobacco and alcohol use,
along with poor oral hygiene [10, 18]. Further, HPV(+)
OPSCC tumours have a different biological disease profile,
presenting at earlier T stages with advanced N stages, and
pathologically as poorly differentiated, non-keratinizing
tumours [19]. Finally, HPV(+) OPSCC tumours have been
associated with improved overall survival (OS) as well as
disease free survival over other HNSCCs [20–23].
The aim of this population based study was to assess
disease patterns and outcomes in OPSCC patients
treated at the provincial HNC referral center, the Nova
Scotia Cancer Centre (NSCC), between 2010 and 2011
with the intention of comparing provincial trends with
those that have been appreciated elsewhere in North
America, Europe, Japan and Australia. There have been
many studies examining the differences in patient and dis-
ease characteristics of HPV(+) versus HPV(-) HNSCCs.
Due to the increasing prevalence of HPV(+) SCCs within
the oropharynx, our study sought to determine if the Nova
Scotian population with HNC demonstrated similar trends
as previously studied HPV(+) populations when OPSCCs
are grouped together regardless of HPV status and com-
pared to other HNSCCs.
Methods
Data for this study was collected as part of a Canada-
wide study on HNSCCs and HPV incidence currently
underway. Capital Health Research Ethics Board ap-
proval was attained prior to this study. Following
approval, a retrospective chart review was performed for
all patients presented at the 2010 and 2011 NSCC’s head
and neck tumour board rounds. With the NSCC acting
as the province-wide HNC referral centre, all Nova Sco-
tia (NS) head and neck oncology cases are discussed
within this forum.
Patient inclusion criteria consisted of patients diagnosed
between January 2003 and December 2011 within NS with
a pathologically confirmed invasive squamous cell carcin-
oma of the oropharynx, lip/oral cavity, nasopharynx, hypo-
pharynx, larynx, salivary glands, nasal cavity or paranasal
sinuses. Patients were excluded if they were diagnosed in
another province, presented with a non-SCC HNC, pre-
sented with a primary tumour site not specified in the
inclusion criteria, or if tissue pathology reports were not
included in their charts.
Patient characteristics analyzed included age at diagno-
sis, sex, ethnicity, birth place, education, occupation,
smoking history, alcohol history, illicit drug history, family
medical history, height, weight, comorbidities including
prior cancer history and ECOG performance status at
diagnosis. The prevalidated Charlson Comorbidity Index
and Charlson probability of 10 year survival will be used
to quantify the comorbidities identified [24]. Disease
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characteristics included anatomic cancer site, anatomic
cancer subsite, stage, grade, histology and p16 staining
(the most commonly used surrogate marker for HPV sta-
tus) [23]. Testing for p16 was performed routinely on pri-
maries of the base of tongue and tonsillar region and at
the surgeon/pathologist’s discretion otherwise. Primary
treatment details (treatment within the first 5 months of
therapy initiation) and outcomes, including recurrence
rates and survival within the follow- up period were also
collected, with follow-up defined as the last clinical
encounter prior to September 2013. Patients were de-
identified and data was entered into a database on a
password-protected computer.
Statistical analysis
The two types of HNC were compared using chi-square
tests for dichotomous categorical variables or Fishers exact
test where appropriate. Wald test was used to compare
variables with 3 categories. Continuous variables were
compared using the non-parametric Wilcoxon test. The
primary outcome was disease-free survival defined as sur-
vival free of relapse. Death was treated as a competing risk
and reported as relapse-free mortality. Data was censored
on date of last known follow-up. Overall survival was ana-
lyzed as a secondary outcome. All events were measured
from the date of diagnosis. Gray’s test for equality of
cumulative incidence functions was used to assess differ-
ences between types of HNC. The cumulative incidence of
mortality in the presence of relapse was also modeled.
Cumulative incidence looks at the probability of relapse
conditional on relapse free survival and competing risk for
survival adjusting for the risk of death.
The proportional hazards model for subdistribution
was used to model the cumulative incidence of relapse
and relapse-free mortality [25]. Univariate competing
risk regression models were performed to look at type of
HNC. Multivariate models were used adjusting for
COPD, age, overall stage, treatment and previous malig-
nancy. Linearity of continuous variables and propor-
tional hazards assumption of categorical variables was
tested. Age violated assumptions of linearity and was
therefore modeled as age < 55 vs. age ≥ 55. Overall sur-
vival was characterized using Kaplan-Meier plots and
the Log-rank test was used to compare type of HNC.
Cox-proportional hazards model was used to estimate
hazard ratios. Level of significance was set at α = 0.05.
SAS STAT software v9.3 (Cary, NC: SAS Institute Inc.)
was used for all analyses.
Results
Primary subsite distribution
There were 582 charts reviewed with 318 (55 %) pa-
tients meeting the inclusion criteria. Of those analyzed,
122 (38 %) had been diagnosed with OPSCC and 196
(62 %) patients had other HNSCC primaries (Table 1).
Analysis was performed on all available data. However,
there were varying levels of availability in patient charts
as demonstrated by the variability in sample sizes for
specific comparisons.
Demographics, risk factors and comorbidities
Patients’ demographics, risk factors and comorbidities
are reported in Table 2. There were no significant differ-
ences in smoking history between patients with OPSCC
and other types of HNC (n = 312, never smoked
21(17 %) vs 25(13 %), current smoker 48(39 %) vs 91(46 %)
and quit smoking 53(43 %) vs 74(38 %), p = 0.3002). The
same was shown when pack year history was analyzed
(Current smokers: 41.5 % vs 44.09 % p = 0.9891; Quit
smoking: 27.79 % vs 32.18 %, p = 0.2969). Those with
OPSCC, however, were significantly less likely to have
COPD as a co-morbidity (n = 318, 19(16 %) vs
53(27 %), p = 0.0175). Particularly of note there were no
significant differences in patients diagnosed at age <55 years
(n = 316, 91(75 %)) compared to those age 55 years
and older (147(75 %), p = 0.8123), in patient gender
(n = 318, males: 97(80 %) vs. 140(71 %), p = 0.1078), in
marijuana use (n = 128, 10(8 %) vs 17(9 %), p = 0.8267)
or in drinking status (n = 267, never drank 4(3 %) vs
8(4 %), current drinker 84(69 %) vs 126(64 %) and quit
drinking 20(16 %) vs 25(13 %), p = 0.7538). Finally, the
Charlson probability for 10 year survival demonstrated
no significant difference (n = 318, >50 % 89(28 %) vs
140(44 %), p = 0.7984).
Treatment and weight loss
Treatment and weight loss data is summarized in
Table 3. These comparisons demonstrated that OPSCCs
were more likely to be given combination therapy, in-
cluding “surgery and radiation therapy” (S-RT), “surgery
Table 1 Anatomical subsite distribution of HNSCC primary
tumours
Site Frequency (n) Percent
Oropharynx 122 38.4 %
Lip & Oral Cavity 86 27.0 %
Larynx 72 22.6 %
Hypopharynx 15 4.7 %
Nasopharynx 10 3.1 %
Nasal Cavity 8 2.5 %
Paranasal Sinuses 4 1.3 %
Salivary Glands 1 0.3 %
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and chemotherapy”, and “surgery, radiation therapy and
chemotherapy” (S-CRT), as initial treatment as com-
pared to other HNSCCs (n = 313, 84(69 %) vs 76(39 %),
p = <0.001). OPSCCs were also significantly less likely to
have primary surgery as initial treatment than other
HNSCCs (n = 313, 14(11 %) vs 93(47 %), p = <0.001).
During therapy, patients with OPSCCs also experienced
greater weight loss by the end of treatment (n = 280,
mean difference −3.0 kg (±5.3 SD), p < 0.001) and at
follow-up (n = 251, mean difference −1.9 kg (± 9.0 SD),
p = 0.0457).
Disease characteristics
Disease characteristics are reported in Table 4. In terms
of pathology, OPSCC tumours were more likely to be
poorly differentiated/undifferentiated (n = 267, 49(40 %)
vs 42(21 %), p < 0.001), be non-keratinizing (n = 169,
25(20 %) vs 17(9 %), p < 0.001), greater than 2 cm on
presentation (n = 253, 72(59 %) vs 78(40 %), p = 0.0061),
have had locoregional nodal spread (n = 315, 103(84 %)
vs 55(28 %), p < 0.001) and to be overall stage 4 (n = 313,
55(45 %) vs 64(33 %), p = 0.0315). In the subset of 57
patients that had p16 testing for HPV, OPSCC were
Table 2 Demographics and risk factors
Demographics/risk factors Oropharygneal Non-oropharyngeal p-value*
Age at Diagnosis (n = 316) <55 31(25 %) 47(24 %) 0.8123
≥55 91(75 %) 147(75 %)
Unknown 0(0 %) 2(1 %)
Sex (n = 318) Female 25(20 %) 56(29 %) 0.1078
Male 97(80 %) 140(71 %)
Unknown 0(0 %) 0(0 %)
Family Hx of Cancer (n = 245) No 27(22 %) 41(21 %) 0.4858
Yes 79(65 %) 98(50 %)
Unknown 16(13 %) 57(29 %)
Cancer History (n = 318) None 93(76 %) 143(73 %) 0.5262a
HNC 4(3 %) 12(6 %)
Other 25(20 %) 41(21 %)
Unknown 0(0 %) 0(0 %)
Smoking History (n = 312) Never 21(17 %) 25(13 %) 0.3002a
Quit 53(43 %) 74(38 %)
Current 48(39 %) 91(46 %)
Unknown 0(0 %) 6(3 %)
Alcohol History (n = 267) Never 4(3 %) 8(4 %) 0.7538a
Quit 20(16 %) 25(13 %)
Current 84(69 %) 126(64 %)
Unknown 14(11 %) 37(19 %)
Marijuana Use (n = 128) No 41(34 %) 60(31 %) 0.8267
Yes 10(8 %) 17(9 %)
Unknown 71(58 %) 119(61 %)
COPD (n = 318) No 103(84 %) 143(73 %) 0.0175
Yes 19(16 %) 53(27 %)
Unknown 0(0 %) 0(0 %)
Pack-Year History (n = 312) Never 0 0 n/a
Current 41.512 yrs. 44.089 yrs. 0.9891b
Quit 27.791 yrs. 32.175 yrs. 0.2969b
Charlson Prob. 10-Yr. Survival (n = 318) <50 % 33(10 %) 56(18 %) 0.7984
>50 % 89(28 %) 140(44 %)
Unknown 0(0 %) 0(0 %)
*α = 0.05, significant results in bold using chi-square test; aWald test applied. bnon-parametric Wilcoxon test applied
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more likely to be p16(+) (37(30 %) vs 1(1 %), p < .001)
compared to other HNSCCs.
Patient prognosis
Prognostic data by HNSCC primaries are presented in
Tables 5, 6 and 7. 26.73 % (85) of patients experienced
relapse (median follow-up time 1.4 years, IQR 0.57 to
1.74). During follow-up 11.64 % (37) died without
relapse (median follow-up time 0.7 years, IQR 0.28 to
1.05). The cumulative incidence of relapse at 1-year was
7.03 % (95 % CI 3.26 % to 12.74 %) for OPSCCs com-
pared to 20.61 % (95 % CI 14.93 % to 26.95 %) in other
HNSCCs (Table 5). The Gray test indicated a difference
in cummulative incidence functions (Fig. 1) for relapse
between OPSCC and non-OPSCC tumours (p = 0.0042).
However there was no evidence of a difference between
Table 4 Disease characteristics
Pathological factors Oropharygneal Non-oropharyngeal p-value*
Tumour size (n = 253) ≤2 31(25 %) 72(37 %) 0.0061
>2 72(59 %) 78(40 %)
Unknown 19(16 %) 46(23 %)
Node Status (n = 315) Negative 19(16 %) 138(70 %) <0.0001
Positive 103(84 %) 55(28 %)
Unknown 0(0 %) 3(2 %)
Metastasis (n = 313) No 121(99 %) 190(97 %) 0.5242
Yes 0(0 %) 2(1 %)
Unknown 1(1 %) 4(2 %)
Overall TMN Stage (n = 313) <4 66(54 %) 128(65 %) 0.0315
4 55(45 %) 64(33 %)
Unknown 1(1 %) 4(2 %)
Keratinization (n = 169) Non-Keratinizing 25(20 %) 17(9 %) <0.0001
Keratinizing 33(27 %) 94(48 %)
Unknown 64(52 %) 85(43 %)
Grade (n = 267) ≥3 49(40 %) 42(21 %) <0.0001a
2 41(34 %) 108(55 %)
1 1(1 %) 26(13 %)
Unknown 31(25 %) 20(10 %)
p16 Status (n = 57) Negative 8(7 %) 11(6 %) <0.0001
Positive 37(30 %) 1(1 %)
Unknown 77(63 %) 184(94 %)
* α = 0.05, significant results in bold using chi-square test; aWald test applied
Table 3 Primary treatments and weight loss
Primary treatment/weight Loss Oropharygneal Non-oropharyngeal p-value*
Combination Therapy (n = 313) No 35(29 %) 118(60 %) <0.0001
Yes 84(69 %) 76(39 %)
Unknown 3(2 %) 2(1 %)
Primary Surgery (n = 313) No 105(86 %) 101(52 %) <0.0001
Yes 14(11 %) 93(47 %)
Unknown 3(2 %) 2(1 %)
Median Weight Loss (kg)
by Treatment End (n = 280)
−5.7(31.4b) −1.3(37.3b) <0.0001a
Median Weight Loss (kg)
at Follow-up (n = 251)
−6.9(48.5b) −4.5(66.45b) 0.0457a
*α = 0.05, significant results in bold using chi-square test; anon-parametric Wilcoxon test applied; bweight loss range
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the groups for the cummulative incidence function
(Fig. 2) for relapse free mortality (p = 0.1167). The cu-
mulative incidence of relapse free mortality at 1-year
was 9.76 % (95 % CI 5.13 % to 16.16 %) for OPSCCs
compared to 7.76 % (95 % CI 4.43 % to 12.28 %) for
non-OPSCC tumours (Table 5).
In univariate analysis, the hazard of relapse was 2.119
times greater for non-OPSCC tumors (p = 0.0034) than
OPSCCs. After adjusting the risk model for age ≥ 55,
overall stage, treatment, COPD and previous malig-
nancy, the hazard of relapse was 1.899 (95 % CI 0.998 to
3.611, p = 0.0.0505). The hazard of relapse-free mortality
in univariate analysis was 0.636 times less for non-
OPSCC tumors (p = 0.053) than OPSCCs. In multivari-
ate analysis after adjusting for age ≥ 55, overall stage,
treatment, COPD and previous malignancy, the hazard
of relapse-free mortality was 0.896 (95 % CI 0.366 to
2.194, p = 0.809).
Overall one-year mortality in the non-OPSCC group
was 13.70 % (SE 0.26) and 12.87 % (SE 0.32) in the
OPSCC group (Fig. 3). The log-rank test showed no
evidence of a difference in mortality rate between the
two groups (p = 0.6150). The unadjusted hazard ratio
was 1.13(95 % CI 0.698 to 1.823, p = 0.6229) for death
for non-OPSCC tumours compared to OPSCCs. On
multivariate analysis however, an overall survival was
appreciated. Specfically, after adjusting for age ≥ 55,
overall stage, treatment, COPD and previous malig-
nancy the hazard ratio was 1.822(95 % CI 1.025 to
3.238, p = 0.0408) for overall mortality in the non-
OPSCC group.
Discussion
In this population based study, it was found that the
NS OPSCC population differed from other HNCs in a
similar manner to those previously observed in other
populations, however, there were some notable differ-
ences. Unlike many previous studies there were no
significant differences noted when patient age, sex,
alcohol history or Charlson Comorbidity Indices were
compared between these groups. There was also no sig-
nificant difference elucidated when smoking history
was compared, although OPSCC patients were less
commonly diagnosed with COPD. For this reason it
may be hypothesized that other HNSCC patients had
more exposure to tobacco smoke, although this re-
mains an imperfect metric.
Weight loss comparisons at follow-up and by treat-
ment end demonstrated significantly more weight loss
Table 5 Cumulative incidence of relapse and relapse-free mortality at 1 year
Subsite Cumulative relapse at 1 year (95 % CI) p-value* Cumulative relapse-free mortality at 1 year (95 % CI) p-value*
Oropharynx 7.03 % (3.26–12.74 %) 0.0042 9.76 % (5.13–16.16 %) 0.1167
Non-OPC 20.61 % (14.93–26.95 %) 7.76 % (4.43–12.28 %)
*α = 0.05, significant results in bold using Gray’s test for equality of cumulative incidence
Table 6 Univariate and multivariate competing risk regression analysis for relapse and mortality-free relapse
Variable Category Univariate competing
risk regression (95 % CI)
p-value* Multivariate competing
risk regression (95 % CI)
p-value*
Relapse
Primary site Non-oropharyngeal vs Oropharyngeal 2.119 (1.282–3.501) 0.0034 1.899 (0.998–3.611) 0.0505
COPD Yes vs. No 1.298 (0.777–2.170) 0.3194
Prior Cancer Yes vs. No 1.083 (0.644–1.819) 0.7645
Primary Treatment Surgery vs. Chemotherapy/ Radiation 1.306 (0.734–2.323) 0.3645
Stage Stage 4 vs Other 1.506 (0.930–2.438) 0.0.0960
Age Age≥ 55 vs <55 0.960 (0.587–1.571) 0.8714
Mortality-free Relapse
Primary site Non-oropharyngeal vs Oropharyngeal 0.636 (0.314–1.288) 0.053 0.896 (0.366–2.194) 0.8098
COPD Yes vs. No 1.669 (0.734–3.794) 0.2218
Prior Cancer Yes vs. No 2.507 (1.118–5.624) 0.0258
Primary Treatment Surgery vs. Chemotherapy/ Radiation 0.319 (0.115–.884) 0.0280
Stage Stage 4 vs Other 2.242 (1.084–4.638) 0.0295
Age Age≥ 55 vs <55 2.975 (0.925-9.568) 0.0673
*α = 0.05, significant results in bold using competing risk regression
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in the OPSCC group. This observation may simply be
attributed to the differences in initial treatment be-
tween these two cohorts. As seen in Table 3, non-OPC
HNSCC patients had a 47 % chance of receiving sur-
gery alone compared to 11 % in the OPSCC group with
OPSCCs having a greater chance of receiving combin-
ation therapy (69 % vs. 39 %). During this possible
seven-week course of combination therapy the ability
to have adequate oral intake is frequently severely lim-
ited due to the impact radiotherapy has on swallowing
subsequently resulting in further weight loss.
Mirroring previous populations studied, in terms of
disease characteristics, Nova Scotian patients with
OPSCCs were significantly more likely to have lesions
that were either poorly or undifferentiated, that were
non-keratinizing, overall stage 4, have had nodal spread
and to be HPV(+) compared to other HNSCCs. Interest-
ingly, in a univariate analysis even with these classic
indicators of poor prognosis OPSCCs in our study were
also significantly less likely to experience relapse during
the follow-up period. This was despite the lack of signfi-
cance in the comparison of relapse-free mortality or
overall mortality during the follow-up period. When
these comparisons were adjusted for age ≥ 55, overall
stage, treatment, COPD and previous malignancy in a
multivariate analysis, significance decreased for relapse
although still clinically significant at p=0.0505. However,
significance was gained for overall mortality. This might
suggest a significant interaction between non-OPSCC
HNC and these other prognostic variables. The favorable
Table 7 Univariate and multivariate Cox proportional hazard model analysis of overall mortality
Variable Category Univariate Cox proportional
hazards (95 % CI)
p-value* Multivariate Cox proportional
hazards (95 % CI)
p-value*
Overall mortality
Primary site Non-oropharyngeal vs Oropharyngeal 1.128 (0.698–1.823) 0.6229 1.822 (1.025–3.238) 0.0408
COPD Yes vs. No 2.022 (1.205–3.394) 0.0077
Prior Cancer Yes vs. No 1.622 (0.980–2.683) 0.0599
Primary Treatment Surgery vs. Chemotherapy/Radiation 0.367 (0.212–0.636) 0.0004
Stage Stage 4 vs Other 2.117 (1.306–3.432) 0.0023
Age Age ≥ 55 vs <55 1.721 (0.928–3.193) 0.0850
*α = 0.05, significant results in bold using Cox proportional hazard model
Fig. 1 Cumulative incidence of relapse between oropharnygeal and non-oropharnygeal tumours (p = 0.0042)
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findings in the univarite and multivariate relapse analyses
and the multivariate mortality analysis were in keeping
with data suggesting better outcomes among HPV related
HNSCCs [20–23].
With previous HPV(+) populations demonstrating
similar prognostic trends to our OPSCC group these
findings may simply be attributed to the high percent-
age of HPV(+) tumors within the oropharyngeal site.
This conclusion must be interpreted with caution, how-
ever, as we had such a small proportion of the OPSCC
population having data relating to HPV status. Further-
more, OPSCCs have been shown to demonstrate three
distinct survival curves in the literature with p16+/non-
smokers having the best prognosis, followed by p16+/
smokers and finally p16-/non-smokers doing the worst
[26]. With this in mind, the survival outcomes of our
Fig. 2 Cumulative incidence of relapse free mortality between oropharnygeal and non-oropharnygeal tumours (p = 0.1167)
Fig. 3 Kaplan-Meier curve comparing overall mortality between oropharyngeal (1) and non-oropharyngeal (2) subsites (p = 0.6150)
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OPSCC group are lower than observed in homogeneous
HPV(+) OPSCC populations. This suggests that the
HPV(-) OPSCC cohort is influencing these results to some
degree and that Nova Scotia’s relatively high smoking rate
may be placing more patients on the intermediate survival
curve described above [26, 27].
The recurrence free survival advantage of OPSCCs has
been attributed to the tumours’ improved response pro-
files as compared to other HNSCCs with HPV(+) tu-
mours responding better to chemotherapy and radiation
[9, 21, 28, 29]. CRT is, however, associated with
increased acute and late toxicities significantly affecting
quality of life post-treatment [30]. It has also been
shown that combination therapy including surgery for
OPSCC has an improved 5-year disease specific survival
in stage 3 and 4 disease compared to S-RT and CRT
alone [31]. Furthermore, there has been an increase in
studies investigating whether we can safely de-escalate
treatment for HPV(+) OPSCCs at low risk for distant
metastasis, with hopes that treatment related morbidity
can be reduced without sacrificing survival outcomes
[32–34]. This comes at a time when surgical techniques
such as transoral robotic surgery are being developed
and tested as possible alternatives to CRT. Recently,
these modalities have compared favorably in terms of
survival and quality of life in preliminary studies [35].
Evidence is now accumulating suggesting that the
classic IUCC/AJCC TNM staging system used to prog-
nosticate HNCs might be inadequate due to the unique
presentation and treatment response profile of OPSCCs
[36–38]. Most studies show HPV(+) OPSCCs tend to
have more nodal spread and higher overall TNM stages
than other subsites despite improvements in OS and
disease free survival [19–21, 36, 37, 39]. Our research
would further support this notion with Nova Scotian
OPSCCs presenting at higher overall TNM stages. Des-
pite this, these patients experienced a more favorable
prognosis as compared to their HNSCC counterparts
in terms of relapse and mortality thus supporting HPV
status as a useful prognostic indicator [24, 36, 37].
Our findings would suggest that an alternative sta-
ging system might be warranted for this particular sub-
set of SCC. This concept is not new, as the IUCC/
AJCC staging system for HNC has been scrutinized for
years to further improve its suboptimal prognostic
ability [40]. Other staging systems have been developed
for HNC in an attempt to mitigate this deficit but there
has yet to be an appropriate alternative shown to be
effective [40–42]. Notably Huang et al. have shown that
an alternative anatomical stage grouping has superior
prognostic ability to the classic system and may be fur-
ther enhanced by the addition of non-anatomic factors
[43]. When this new staging system was applied to our
patient cohort there were significantly more OPSCCs
presenting as stage 1 or 2 disease, which better corre-
lates with their improved prognosis (Table 8). These
findings may merit a more in-depth survival analysis in
the future.
Our findings suggest that until the advent of a prog-
nostically accurate staging system that takes HPV status
into account the presence of an oropharyngeal subsite
primary should be considered a positive prognostic
indicator regardless of HPV status. This may be of par-
ticular importance when HPV status is unknown. More
importantly, this highlights the need for universal p16
testing, which is further amplified by recent evidence
demonstrating that p16 positive non-OPSCC tumours
have similarly improved survival outcomes as compared
to p16 negative non-OPSCC tumours [44].
With the disease characteristics of Nova Scotian
OPSCC’s so closely mirroring those of HPV(+) popula-
tions, the oncogenic role of this virus within the oro-
pharynx is further solidified. Although the effect of
HPV vaccination on incidence reduction of OPSCCs
within the population will take many years to become
fully apparent there has been promising research sug-
gesting this is the case [45]. Our findings support
established population based vaccination programs
shown to be effective in both sexes [46].
This study provided some intriguing findings on
OPSCC in NS patients, however, did have some limita-
tions that must be recognized in interpretation. Of
course, any retrospective chart review relies on the ac-
curacy of the written record, the presence of important
information in the record and the accessibility of that
record. For this reason many comparisons have differ-
ent sample sizes based on the availability of patient
data. Further, our interval for follow-up of patients in
this study may not have been of adequate length to
accurately elucidate OS trends for this population. A
Table 8 Comparison of Huang et al.’s recursive partitioning analysis (RPA) staging against IUCC/AJCC staging for the oropharyngeal
subsite
Stages at presentation RPA staging IUCC/AJCC staging p-value*
Oropharyngeal Subsite 1 or 2 92(75 %) 12(10 %) <0.001
3 or 4 29(24 %) 109(89 %)
Unknown 1(1 %) 1(1 %)
*α = 0.05, significant results in bold using chi-square test
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larger sample would also provide increased statistical
power to further study the relationships between our sub-
groups and the prognostic variables analyzed herein.
Finally, HPV status in particular was scarce in patient
records during this time period thus making the exact
influence of the virus difficult to elucidate. While the
population tested for p16 was small, based on trends
within the oropharynx and the characteristics demon-
strated herein it is likely that many of the trends
observed in Nova Scotia’s OPSCC cohort could be
attributed to HPV infection alone. For this reason we
believe that if all patients had been tested the number
of HPV associated OPSCCs would be similar to other
North American populations. The small number of
specimens tested is at least in part due to their date of
diagnosis predating routine p16 testing in NS, which
was implemented in 2009. Although all patients were
treated during 2010 or 2011 only 79 % of them were
diagnosed within this time period. Furthermore, among
these late diagnoses many would have presented with
nodal disease thus limiting the adequacy of p16 testing,
as tissue samples would have been limited to fine nee-
dle aspirates [47].
Conclusions
In conclusion, this study demonstrates that Nova Scotian
patients diagnosed with OPSCCs treated at the NSCC
between 2010 and 2011 did in fact possess disease charac-
teristics distinct from other HNSCC subsites. The disease
characteristics observed were in line with previous studies
on HPV(+) OPSCCs further supporting the potential that
HPV infection is playing an important oncogenic role in
NS. Furthermore, despite more advanced presentations,
based on IUCC/AJCC staging, these OPSCC tumours
tend to have a more favorable prognosis than their other
HNSCC counterparts. These findings support the imple-
mentation of universal p16 testing for accurate prognosti-
cation of HNSCCs and the potential inclusion of p16 into
future staging systems for OPSCC. Ultimately, these
unique Nova Scotian trends when combined with other
studies across Canada should help guide treatment and
prevention resource allocation decisions in the future.
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